Bausch's Lumify Eye Drops Sales Jump To Double Competitors' Market Share
Executive Summary
Lumify redness relief eye drops nearly doubled in sales between Bausch's second and third quarters and drove 7% organic growth of its global consumer business compared to the year-ago period. The brand has double the market share of its two closest competitors, and the firm plans clinical studies for product extensions to the brand in 2020.
You may also be interested in...
Bausch + Lomb Second On Bausch Health IPO Card
Canadian firm plans to separate Solta first, with an IPO in December or January, and at least 30 days later offer shares in Bausch + Lomb. Order of IPOs could change, though.
After NDA Investment For OTC Switch, Success Swings On More Spending For Advertising
Switch consultant Susan Levy suggests drug firms temper enthusiasm for Rx-to-OTC switches with considering the costs NDAs generate and the histories of switches that haven’t been successes.
Bausch Expects US Approval In 2020 Of Preservative-Free OTC Ketotifen Eye Drop
Bausch says it expects US FDA to approve its ANDA for the first preservative-free OTC eye drop for ocular itching associated with allergic conjunctivitis in the second half of 2020. The firm reports its Lumify redness relief drops generated sales of $63m for 2019.